FREELINE
Freeline Therapeutics Limited
Application Filed: 2018-11-23
Trademark Application Details
PUBLISHED FOR OPPOSITION
| Research |
OneLook
Acronym Finder
|
| Serial Number | 79255127 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Samantha M. Quimby |
| Attorney Docket Number | 0641296 |
| Law Office Assigned | M70 |
| Employee Name | BUCHANAN WILL, NORA |
Timeline
| 2018-11-23 | Application Filed |
| 2019-11-13 | Location: PUBLICATION AND ISSUE SECTION |
| 2019-12-17 | Published for Opposition |
| 2019-12-17 | Status: Live/Pending |
| 2019-12-17 | Transaction Date |
| 2019-12-18 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  Freeline Therapeutics Limited |
| Entity Statement | Limited Company/LLP UK, England and Wales |
| Address | Stevenage Bioscience Catalyst, Gunnels Wood Road Stevenage, Herts SG1 GB |
| Legal Entity Type | |
| Legal Entity State | GB |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of genetic or inherited or non-infectious diseases or disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration or prophylaxis of chronic or systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for use in gene therapy for prevention, amelioration or treatment of disorders, namely of blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases |
| GS0051 | Pharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of genetic or inherited or non-infectious diseases or disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration or prophylaxis of chronic or systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for use in gene therapy for prevention, amelioration or treatment of disorders, namely of blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | 2019-03-21 | 1 SDRC M: |
| LIMITATION FROM ORIGINAL APPLICATION ENTERED | 2019-03-25 | 2 LIMI I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2019-03-27 | 3 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2019-03-27 | 4 DOCK D:Assigned to Examiner |
| APPLICATION FILING RECEIPT MAILED | 2019-04-02 | 5 MAFR O:Outgoing Correspondence |
| NON-FINAL ACTION WRITTEN | 2019-04-16 | 6 CNRT R:Renewal |
| NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | 2019-04-17 | 7 RFCR E:E-Mail |
| REFUSAL PROCESSED BY MPU | 2019-05-07 | 8 RFRR P: |
| NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | 2019-05-08 | 9 RFCS P: |
| REFUSAL PROCESSED BY IB | 2019-06-14 | 10 RFNT P: |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-11-06 | 11 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-11-06 | 12 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-11-06 | 13 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2019-11-07 | 14 CNSA O:Outgoing Correspondence |
| ASSIGNED TO LIE | 2019-11-12 | 15 ALIE A:Allowance for Publication |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2019-11-27 | 16 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2019-12-17 | 17 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2019-12-17 | 18 NPUB E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2020-03-03 | 19 R.PR A:Allowance for Publication |
| FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | 2020-06-03 | 20 FICR P: |
| FINAL DISPOSITION PROCESSED | 2020-07-08 | 21 FIMP P: |
| FINAL DISPOSITION NOTICE SENT TO IB | 2020-07-08 | 22 FICS P: |
| FINAL DECISION TRANSACTION PROCESSED BY IB | 2020-07-24 | 23 FINO P: |
| NEW REPRESENTATIVE AT IB RECEIVED | 2022-08-15 | 24 NREP P: |
| CHANGE OF NAME/ADDRESS REC'D FROM IB | 2023-02-06 | 25 ADCH M: |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 